Trial · NCT04194944
Results by group40
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 40
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (With Pembrolizumab) | Selpercatinib (TRT A) | 24.84 | 95% Confidence Interval 16.89 to NA | Months | |
| Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (With Pembrolizumab) | Pemetrexed and Platinum With Pembrolizumab (TRT B) | 11.17 | 95% Confidence Interval 8.77 to 16.76 | Months | |
| PFS by BICR (With or Without Pembrolizumab) | Selpercatinib (TRT A) | 24.84 | 95% Confidence Interval 17.31 to NA | Months | |
| PFS by BICR (With or Without Pembrolizumab) | Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) | 11.17 | 95% Confidence Interval 8.77 to 16.76 | Months | |
| Percentage of Participant With Disease Control Rate (DCR) by BICR (With Pembrolizumab) | Selpercatinib (TRT A) | 89.1 | 95% Confidence Interval 82.5 to 93.9 | Percentage of Participants | |
| Percentage of Participant With Disease Control Rate (DCR) by BICR (With Pembrolizumab) | Pemetrexed and Platinum With Pembrolizumab (TRT B) | 84.3 | 95% Confidence Interval 74.7 to 91.4 | Percentage of Participants | |
| Percentage of Participant With DCR by BICR (With or Without Pembrolizumab) | Selpercatinib (TRT A) | 89.3 | 95% Confidence Interval 83.4 to 93.7 | Percentage of Participants | |
| Percentage of Participant With DCR by BICR (With or Without Pembrolizumab) | Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) | 82.4 | 95% Confidence Interval 73.6 to 89.2 | Percentage of Participants | |
| PFS2 (With Pembrolizumab) | Selpercatinib (TRT A) | NA | 95% Confidence Interval NA to NA | Months | |
| PFS2 (With Pembrolizumab) | Pemetrexed and Platinum With Pembrolizumab (TRT B) | NA | 95% Confidence Interval NA to NA | Months | |
| PFS2 (With or Without Pembrolizumab) | Selpercatinib (TRT A) | NA | 95% Confidence Interval NA to NA | Months | |
| PFS2 (With or Without Pembrolizumab) | Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) | NA | 95% Confidence Interval NA to NA | Months | |
| Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR (With Pembrolizumab) | Selpercatinib (TRT A) | 83.7 | 95% Confidence Interval 76.2 to 89.6 | Percentage of participants | |
| Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR (With Pembrolizumab) | Pemetrexed and Platinum With Pembrolizumab (TRT B) | 65.1 | 95% Confidence Interval 53.8 to 75.2 | Percentage of participants | |
| ORR: Percentage of Participants With CR or PR by BICR (With or Without Pembrolizumab) | Selpercatinib (TRT A) | 83.6 | 95% Confidence Interval 77.0 to 89.0 | Percentage of Participants | |
| ORR: Percentage of Participants With CR or PR by BICR (With or Without Pembrolizumab) | Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) | 62.7 | 95% Confidence Interval 52.6 to 72.1 | Percentage of Participants | |
| Duration of Response (DoR) by BICR (With Pembrolizumab) | Selpercatinib (TRT A) | 24.18 | 95% Confidence Interval 17.94 to NA | Months | |
| Duration of Response (DoR) by BICR (With Pembrolizumab) | Pemetrexed and Platinum With Pembrolizumab (TRT B) | 11.47 | 95% Confidence Interval 9.66 to 23.26 | Months | |
| DOR by BICR (With or Without Pembrolizumab) | Selpercatinib (TRT A) | 24.18 | 95% Confidence Interval 17.94 to NA | Months | |
| DOR by BICR (With or Without Pembrolizumab) | Pemetrexed and Platinum With or Without Pembrolizumab (TRT B) | 11.99 | 95% Confidence Interval 9.69 to 23.26 | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04194944/results